Veterinary MedicinePharmacokineticsPharmacologyDrug InteractionsDrug MetabolismPharmacogeneticsCytochrome P450 EnzymesCytochrome P450 InteractionsCytochrome P450-mediated MetabolismDrug Metabolism GeneticsDrug ResponseDrug-drug Interactions In MetabolismAdverse Drug ResponseCyp2d6 Drug MetabolismCyp2d6 PharmacogeneticsCytochrome P450 Drug MetabolismCytochrome P450 Enzyme InductionCytochrome P450 Enzyme InhibitionCytochrome P450 Genetic PolymorphismMetabolic Enzyme Polymorphism
Cytochrome P450 enzymes, particularly CYP3A4 and CYP2D6, metabolize the majority of drugs, and genetic polymorphisms or drug‑induced changes can cause clinically significant drug‑drug interactions and adverse reactions, though routine genotype testing has yet to demonstrate improved outcomes. The study seeks to catalogue the most important CYP450‑metabolized drugs and the strongest inhibitors and inducers to help clinicians minimize adverse drug reactions and interactions.
Cytochrome P450 enzymes are essential for the metabolism of many medications. Although this class has more than 50 enzymes, six of them metabolize 90 percent of drugs, with the two most significant enzymes being CYP3A4 and CYP2D6. Genetic variability (polymorphism) in these enzymes may influence a patient's response to commonly prescribed drug classes, including beta blockers and antidepressants. Cytochrome P450 enzymes can be inhibited or induced by drugs, resulting in clinically significant drug-drug interactions that can cause unanticipated adverse reactions or therapeutic failures. Interactions with warfarin, antidepressants, antiepileptic drugs, and statins often involve the cytochrome P450 enzymes. Knowledge of the most important drugs metabolized by cytochrome P450 enzymes, as well as the most potent inhibiting and inducing drugs, can help minimize the possibility of adverse drug reactions and interactions. Although genotype tests can determine if a patient has a specific enzyme polymorphism, it has not been determined if routine use of these tests will improve outcomes.
18
Oral Erythromycin and the Risk of Sudden Death from Cardiac Causes
Wayne A. Ray, Katherine T. Murray, Sarah Meredith et al. · New England Journal of Medicine · 2004 · 499 citations · Full text
Medicine, Gynecology, Obstetrics +9
The hypoalgesic effect of tramadol in relation to CYP2D6*
Lars K. Poulsen, Lars Arendt‐Nielsen, Kim Brøsen et al. · Clinical Pharmacology & Therapeutics · 1996 · 387 citations